GlassScriptPhysician profile
Jason L Crytzer
NPI 1801883681
$4,453.72
in general payments reported to CMS, 2019-2025
27 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,262 · 2022: $1,430 · 2023: $875 · 2024: $517 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,200.64 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $612.04 | 2021-2022 | |
| Philips North America LLC | $492.18 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $423.64 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $288.59 | 2021-2023 | Farxiga |
| Abbott Laboratories | $159.29 | 2023-2024 | Cardiomems, Mitraclip |
| Novartis Pharmaceuticals Corporation | $150.42 | 2022-2025 | |
| Endologix LLC | $149.32 | 2025 | Torus Stent Graft System, Endocross Device |
| Impulse Dynamics (USA) INC. | $139.31 | 2021-2023 | Optimizer |
| Merck Sharp & Dohme LLC | $133.85 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $101.91 | 2021 | |
| Sanofi-Aventis U.S. LLC | $94.10 | 2021-2023 | |
| Novo Nordisk INC | $87.83 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Baxter Healthcare | $58.17 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Pfizer INC. | $57.71 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $50.42 | 2021 | |
| Astellas Pharma US INC | $39.99 | 2021 | |
| Cvrx, INC. | $39.51 | 2024 | Barostim Neo System |
| Amgen INC. | $34.50 | 2021-2023 | Repatha |
| Lexicon Pharmaceuticals, INC. | $32.69 | 2023-2024 | |
| Kerecis Limited | $25.20 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Kestra Medical Technology Services, INC. | $21.58 | 2023 | Assure Wcd |
| Medtronic, INC. | $15.65 | 2022 | |
| Chiesi USA, INC. | $14.29 | 2022 | |
| Bardy Diagnostics, INC. | $13.79 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $11.15 | 2021 | |
| Althera Pharmaceuticals LLC | $5.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Crytzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.